Eurobio Scientific Strengthens Capital with 88.9% Acquisition by EB Development

In a strategic move to bolster its growth and development, Eurobio Scientific has announced that EB Development, with the backing of NextStage AM and IK Partners, has successfully acquired 88.92% of its share capital through a takeover bid. Following a reopening period, the bid resulted in the acquisition of over 5.2 million ordinary shares, thus enabling significant control while narrowly missing the 90% threshold required for a squeeze-out procedure. As a result, the additional price of €1.25 per share will not be paid. This transaction underscores the collaborative efforts between key players including EB Development, NextStage AM—who initially acquired a stake in 2022 through EurobioNext—and IK Partners, a major force in private equity. The significant investment positions Eurobio Scientific for accelerated growth, particularly in its in vitro diagnostics and intelligent health sectors. Denis Fortier, Chairman and CEO of Eurobio Scientific, expressed confidence in this partnership, seeing it as a leverage point for future expansion and innovation. Key spokespersons from NextStage AM and IK Partners have shared their enthusiasm and aligned vision for Eurobio’s potential to lead within its market. The transaction is anticipated for settlement on December 23, 2024.